Minerva Neurosciences, Inc. (NERV)

NASDAQ: NERV · IEX Real-Time Price · USD
2.580
+0.060 (2.38%)
At close: Mar 28, 2024, 4:00 PM
2.530
-0.050 (-1.94%)
After-hours: Mar 28, 2024, 5:20 PM EDT

Company Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.

Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.

Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Minerva Neurosciences, Inc.
Minerva Neurosciences logo
Country United States
Founded 2007
IPO Date Jul 1, 2014
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Dr. Remy Luthringer Ph.D.

Contact Details

Address:
1601 Trapelo Road, Suite 286
Waltham, Massachusetts 02451
United States
Phone 617-600-7373
Website minervaneurosciences.com

Stock Details

Ticker Symbol NERV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001598646
CUSIP Number 603380205
ISIN Number US6033802058
Employer ID 26-0784194
SIC Code 2834

Key Executives

Name Position
Dr. Remy Luthringer Ph.D. Executive Chairman and Chief Executive Officer
Geoffrey Robin Race F.C.M.A., M.B.A. President
Frederick W. Ahlholm CPA Senior Vice President, Chief Financial Officer and Secretary
Joseph Reilly Senior Vice President and Chief Operating Officer
William B. Boni Vice President of Investor Relations and Corporate Communications
Prof. Michael Davidson M.D. Chief Medical Officer
Dr. Ramana Kuchibhatla Ph.D. Senior Vice President and Head of Research and Development

Latest SEC Filings

Date Type Title
Feb 27, 2024 8-K Current Report
Feb 26, 2024 10-K/A [Amend] Annual report
Feb 22, 2024 10-K Annual Report
Feb 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2023 10-Q Quarterly Report
Sep 28, 2023 8-K Current Report
Aug 15, 2023 ARS Filing
Aug 15, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 15, 2023 DEF 14A Other definitive proxy statements